US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Major Depressive Disorder · Migraine · AXSM
Axsome Therapeutics
Axsome Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
One World Trade Center, New York, NY 10007, US HQ
2012 Founded
981 Employees
Public company Type
AXSM · NYSE Ticker
Company details
- Status
- Public
- HQ
- One World Trade Center, New York, NY 10007, US
- Founded
- 2012
- Employees
- 981
- Programs
- 28
- Drugs
- 12
- Patents
- 162
Axsome Therapeutics pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Axsome Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Axsome Therapeutics in public FDA and regional records.
-
Development asset linked to Axsome Therapeutics in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.
- Mechanism
- Dopamine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter inhibitor
-
US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to Axsome Therapeutics in public FDA and regional records. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Axsome Therapeutics in public FDA and regional records. Mechanism: Serotonin 1b (5-HT1b) receptor agonist.
- Mechanism
- Serotonin 1b (5-HT1b) receptor agonist
-
solriamfetol
Nervous system (N06)US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Axsome Therapeutics in public FDA and regional records.
-
Development asset linked to Axsome Therapeutics in public FDA and regional records.
-
Development asset linked to Axsome Therapeutics in public FDA and regional records.